Cambridge Healthtech Institute’s 5th Annual
Novel Antibody Constructs and Alternative Scaffolds
Innovative Engineering, Novel Products, Unique Targets and Immune Modulation
5-6 November 2014
In-depth research with the industry reveals the emergence of a wide range of exciting and innovative technologies with a variety of applications. In Europe there is a strong focus on platforms for bi-specific products, and on unique constructs and scaffolds, particularly on Fc engineering. This conference will present platforms for novel biotherapeutics with improved features such as enhanced access to the target site and better binding, and unique modes of action such as immune and complement activation. Presentations will cover target selection, and drug and platform discovery and development, and include challenges overcome and evidence for efficacy.
Seamless Transition from Mono- to Multi-Specific Antibodies Based on Light Chain Diversity
Nicolas Fischer, Ph.D., Head, Research, NovImmune SA
Benefits of Bispecific Antibodies with Two Independent Paratopes in the Fv Region
Roland Beckmann, Ph.D., CEO, CSO, Dutalys
A Novel Monovalent-Bispecific IgG Design
Partha S. Chowdhury, Ph.D., Principal Scientist, Antibody Discovery and Protein Engineering, MedImmune, Inc.
Antibody Engineering for Fc Silencing
Tilman Schlothauer, Ph.D., Senior Scientist, Functional Assays, Roche Diagnostics GmbH
Structural and Functional Insights into Neonatal Fc Receptor-Based Recycling Mechanisms
William Dall’Acqua, Ph.D., Director, R&D, Antibody Discovery and Protein Engineering-ADPE, MedImmune, Inc.
Philosophy and Principal Dogma behind Modern Discovery & Development of Biologics
Ralf Schumacher, Ph.D., Site Head, Large Molecule Research, Roche Penzberg & pRED
Protein Inactivation in vivo in Intrabody Expressing Mice
Stefan Dübel, Ph.D., Director, Biotechnology, Technische Universität Braunschweig
Natural and Engineered Sortases for the Masses: A New Enabling Technology for Protein Engineers
Christian Freund, Ph.D., Professor, Biochemistry, Freie Universitaet Berlin
Rationalising the Pharmacological Effect of a High-Affinity Neutralizing Serpin Antibody through Co-Crystallography
Katherine Vousden, Ph.D., Senior Scientist, Antibody Discovery and Protein Engineering, MedImmune
Receptor-Mediated Delivery of a Bispecific Antibody into the Primate Brain: Challenges and Safety Findings
Mark S. Dennis, Ph.D., Principal Scientist, Antibody Engineering, Genentech, Inc.
Engineering Brain Shuttle Antibodies
Jens Niewöhner, Ph. D., Principal Scientist, Large Molecule Research, Pharma Research and Early Development, Roche Diagnostics GmbH
Engineering of Probodies: Antibodies that Become Activated at the Target Site and Target Widely-Expressed Tumor-Specific Antigens
James West, Ph.D., Research Fellow, Protein Engineering, CytomX Therapeutics, Inc.
Novel Affitin Designs: Structural Basis for Two Modes of Action for Potent and Specific Inhibition of Glycosidases
Frédéric Pecorari, Ph.D., Researcher, Cancer Research Center of Nantes-Angers, University of Nantes
T Cell Redirection for Immune And Allergic Disorders
David Urech, Ph.D., CSO and Co-CEO, Numab AG
SM201/SM211: Two Anti-FcyRIIB mAbs Differing by a Single Amino Acid with Distinct Immunomodulatory Properties for the Treatment of Autoimmune Diseases
Peter Sondermann, Ph.D., CSO, SuppreMol GmbH